April 1, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Notice of Personnel Changes at SymBio Pharma USA, Inc.
TOKYO, April 1, 2024 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) today
announced the appointment of John Houghton as CEO and President of SymBio Pharma USA, Inc.
(established in May 2016; wholly owned US subsidiary, “SPU”), effective April 1, 2024, replacing
Stephane Berthier, who was previously CEO and President of SPU. With this appointment, SPU willdevelop its full-scale operations with a mission to drive the development of the intravenous
formulation of brincidofovir (“IV BCV”) toward commercialization in Europe, the U.S., Japan and theUK.
Statement from Mr. John Houghton: “I am deeply honored to join SymBio at this pivotal juncture in
their journey, as they aim to emerge as a leading global specialty biopharmaceutical company
committed to delivering hope to patients in need. Collaborating with SymBio’s experienced
professionals, I am convinced that we can elevate the company to unprecedented heights. Together,
we will advance SymBio’s mission of identifying, developing, and delivering innovative therapeutic
solutions to patients suffering in underserved therapeutic areas, making meaningful contributions tohealthcare.”Statement from Fuminori Yoshida, President and CEO of SymBio: “I am pleased to announce theappointment of Mr. John Houghton as the new CEO and President of SymBio Pharma USA. John isan accomplished industry leader with more than 30 years of experience both with major
pharmaceutical companies as well as start-up biotech companies, including leading one to a public
listing in the US. With his vast experience in building global business and proven leadership skills,
John will undoubtedly bring value and drive to the growth and expansion of our global business. I am
confident that under his leadership, SymBio Pharma USA will continue to thrive and achieve key
milestones in this transformative phase of the company.”
SymBio Pharma USA, Inc. (summary)
Name

SymBio Pharma USA, Inc. (SPU)

Address

Durham, North Carolina, USA

Representative

John Houghton

Establishment Date

May 10, 2016

Shareholders

A 100% subsidiary of SymBio Pharmaceuticals Limited

Business Activities

Research and development of pharmaceutical products

11.

Name and Title

NameJohn Houghton

Title
CEO and President of SPU

2.

Date of appointment: April 1, 2024

3.

Profile of the newly appointed President and CEO of SPU
1987
1992
2000
2005
2007
2012
2015
2021
2024

Sales Rep., CYANAMID OF GREAT BRITAIN Ltd., Gosport, UK
Marketing Manager – Respiratory & Business Planning, RHONE-POULENC RORER Ltd.,West Malling and Eastbourne, UK
Disease Group Head, New Products Commercialization, Global Marketing & Medical,
AVENTIS, Bridgewater, N.J.
Vice President, Global Sales & Marketing, STRYKER BIOTECH, Hopkinton,
Massachusetts, USA
President & CEO and Board Director, CORMEDIX, INC., Bridgewater, New Jersey, USA(A public pharmaceutical company)
President & CEO, Acting CFO and Board Director, NEPHROS, INC., River Edge, NewJersey, USA (A public Medical Device company)
Global Franchise Head – Roxadustat, ASTRAZENECA, Gaithersburg, Maryland, USA (Apublic pharmaceutical company)
President & CEO and Board Director, AVOTRES, INC. Cedar Knolls, New Jersey, USA (Aprivate Biotech company)
April 1: Join SymBio Pharma USA, Inc.
BSc (Hons) Sport Science, Liverpool John Moores University (Liverpool, England)
GCE ‘A’ Levels: Physics; Mathematics, North Notts College of Further Education (Worksop,England)

About SymBio Pharmaceuticals Limited.
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously
served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May
2016, the Company incorporated its wholly owned subsidiary in the U.S., called SymBio Pharma
USA, Inc. (Headquarters: Durham, North Carolina, representative: John Houghton). The Company’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to addressing underserved medical needs.
[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

2